Our Products

Acetadote^®

Acetadote^® (acetylcysteine) is our IV treatment for acetaminophen overdose, the leading cause of drug toxicity in the U.S. It was developed by Cumberland and was the first injectable product available to treat acetaminophen overdose available in this country. Though safe at recommended doses, acetaminophen can cause liver damage with excessive use.

Acetadote is used in the emergency department, the intensive care unit, and hospital inpatient setting to prevent or lessen liver damage from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription medications. Acetadote is FDA-approved for adult and pediatric use.  It is free of EDTA as well as any other stabilizing, chelating, or preserving chemicals and has become a standard of care for the treatment of this potentially life-threatening condition.

For more information, including full prescribing and important safety data visit, www.acetadote.com.

Caldolor^®

Caldolor^® (ibuprofen) was the first injectable therapy approved in the United States for the treatment of both pain and fever. It is indicated in adults and pediatric (newborns) as a sole treatment for the management of mild to moderate pain; as an adjunct to reduce the use of opioids in the management of moderate to severe pain; and for the reduction of fever.

Caldolor provides distinct benefits to physicians treating post-operative pain. In addition to working peripherally at the site of trauma, it also acts centrally to blunt the perception of pain. Clinical trials have shown that Caldolor provides beneficial anti-inflammatory properties while reducing fever, pain, and opioid consumption. Cumberland supplies Caldolor in two presentations – a vial that requires dilution before use and a pre-mixed bag requiring no dilution. The bag presentation is the first and only FDA-approved ready-to-use injectable ibuprofen.

For more information, including full prescribing and important safety data visit, www.caldolor.com.

Kristalose^®

Kristalose^® (lactulose) is the only branded prescription laxative product that combines the established safety and efficacy of lactulose with the convenience and portability of a pre-measured dose. A unique, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient compliance in the treatment of acute and chronic constipation. Kristalose dissolves quickly in 4 oz. of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups.

Kristalose provides a prescription alternative for many patients unable to find relief with over-the-counter laxatives. Additionally, there are no age limitations or length of use restrictions for Kristalose.

For more information, including full prescribing and important safety data visit, www.kristalose.com.

Vaprisol^®

Vaprisol^® (conivaptan) is the first and only intravenously administered vasopressin receptor antagonist, a class of pharmaceuticals developed for the treatment of euvolemic and hypervolemic hyponatremia.  Vaprisol is indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia by reducing excess water in the body and regulating the water/sodium balance. 

Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. It can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure, cancer, and pneumonia.  When partnered with fluid restriction, Vaprisol can provide a positive response in water/sodium balance within 24 hours after beginning therapy.

For more information, including full prescribing and important safety data visit, www.vaprisol.com.

Vibativ^®

Vibativ^® (telavancin) is an FDA-approved injectable antibiotic used in the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.  This lifesaving antibiotic features a dual mode of action designed to treat difficult Gram-positive bacterial infections, including MRSA and those that are classified as multidrug-resistant.  Additionally, clinical data has demonstrated the superior ability of Vibativ to penetrate lung tissue – an important benefit when treating secondary bacterial infections, such as those seen in COVID-19 patients.

For more information, including full prescribing and important safety data visit, www.vibativ.com.

Vasculan^®

Vasculan^®(ifetroban) oral capsule is being developed by Cumberland for the treatment of systemic sclerosis (SSc), also known as scleroderma. It is a rare autoimmune disorder that results in a thickening of the skin and internal organs. With pulmonary disease emerging as the major cause of death in SSc patients, preclinical studies have found that ifetroban can prevent cardiac and lung fibrosis. Following FDA clearance of our IND, we have initiated a Phase II study in SSc patients.

SSc affects 2.5 million people worldwide and does not yet have a proven curative therapy. Although several medications that suppress the immune system are used to slow progression of the disease, there is no universally effective treatment to improve the function of affected internal organs. Hence the treatment of SSc remains an unmet medical need.